By Sabela Ojea
Oncternal Therapeutics said it is reducing its workforce as it discontinues all product development while it goes through a strategic business review.
The clinical-stage oncology company on Thursday said that it will cut its workforce by 37%, equal to about 10 employees, to reduce its operating expenses. The move was unanimously approved by the board of directors a day earlier.
The company, which expects to book termination costs of about $1 million, said the decision comes after the results of ONCT-534 and ONCT-808 didn't show meaningful improvements or anti-tumor activity, respectively.
Oncternal Therapeutics is terminating these studies and will focus on exploring strategic alternatives including asset sales, licensing or other strategic transactions, and a merger, reverse merger or acquisition.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 12, 2024 18:14 ET (22:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。